MDGL Crosses Above Average Analyst Target
December 07, 2017 at 09:25 AM EST
In recent trading, shares of Madrigal Pharmaceuticals Inc (MDGL) have crossed above the average analyst 12-month target price of $60.25, changing hands for $87.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..